OTC · Healthcare
ProPhase Labs, Inc. (PRPH)
As-reported financials and recent SEC filings for ProPhase Labs, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$4.3M
Net income
$-14.7M
Net margin
—
Diluted EPS
$-1.74
ROE
-420.3%
P/E (TTM)
—
Market cap
—
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $4.3M | $6.8M | $35.0M | $122.6M | $79.0M |
| Gross profit | $1.4M | $-150,000 | $15.6M | $70.7M | $42.0M |
| Operating income | $-18.0M | $-38.6M | $-21.2M | $23.6M | $9.8M |
| Net income | $-14.7M | $-53.4M | $-16.8M | $18.5M | $6.3M |
| Diluted EPS | $-1.74 | $-6.67 | $-2.21 | $2.30 | $0.90 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
10-Q2026-06-30
View on EDGAR →10-K2026-06-01
View on EDGAR →NT 10-Q2026-05-15
View on EDGAR →NT 10-K2026-03-27
View on EDGAR →8-K2026-02-13
View on EDGAR →8-K2026-02-13
View on EDGAR →8-K2026-01-27
View on EDGAR →8-K2026-01-23
View on EDGAR →Largest Healthcare peers
Go deeper on PRPH
Search ProPhase Labs, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.